Agents and Actions

, Volume 34, Issue 3–4, pp 387–392 | Cite as

Inhibitory effect of econazole on the release of thromboxanes

  • S. Jancar
  • C. F. P. Teixeira
  • W. Tavares de Lima
  • A. Y. Hoshikawa Fujimura
  • P. Sirois
Inflammation and Immunomodulation


The effect of econazole on the release of thromboxanes was investigated. It was found that econazole inhibited concentration-dependently the aggregation of guinea pig platelets stimulated with arachidonic acid. The compound also reduced significantly the LTB4-induced contraction of guinea pig lung parenchyma strips and the contraction of rabbit aorta to the effluent of LTD4-stimulated guinea pig lungs, both effects mediated mostly by thromboxane generation. The concentration of TXB2 in the effluents from LTD4 stimulated lungs, assayed by EIA, was significantly reduced following pretreatment of the lungs with 10−4M and 10−5M of econazole, whereas the levels of PGE2 were increased. These results demonstrate that econazole is a selective inhibitor of thromboxane synthesis.


Arachidonic Acid PGE2 Selective Inhibitor Thromboxane Lung Parenchyma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    E. F. Godefroi, J. Heeres, J. Van Custen and P. A. J. Janssen,The preparation and antimycotic properties of derivates 1-phenethylimidazole. J. Med. Chem.12, 784–791 (1969).Google Scholar
  2. [2]
    D. Thienpont, J. Van Custen, J. M. Van Nugten, C. J. E. Niemegeers and R. Marsboom,Biological and toxicological properties of econazole, a broad spectrum antimycotic. Arzneimittel-Forsch. (Drugs. Res.)25, 224–230 (1975).Google Scholar
  3. [3]
    T. Kuwahata, I. M. Kobayas, N. Hamamoto and K. Tomiyama,General pharmacology of econazole nitrate. Iyakuhin kenkyu9, 672–691 (1978).Google Scholar
  4. [4]
    S. Ishikawa, S. Manabe and W. Osamu,Miconazole inhibition of platelet aggregation by inhibiting cyclooxygenase. Biochem. Pharmacol.35, 1787–1792 (1986).Google Scholar
  5. [5]
    J. F. Mustard, D. W. Perry, N. G. Ardlie and M. A. Packham,Preparations of suspensions of washed platelets from humans. Br. J. Haematol.22, 193–197 (1972).Google Scholar
  6. [6]
    G. V. R. Born,Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (London)194, 927–929 (1962).Google Scholar
  7. [7]
    P. Sirois, S. Roy and P. Borgeat,The lung paranchymal strip as a sensitive assay for leukotriene B 4. Prostaglandins Med.6, 153–159 (1981).Google Scholar
  8. [8]
    D. M. Engineer, U. Niederhauser, P. J. Piper and P. Sirois,Release of mediators of anaphylaxis: Inhibition of prostaglandin synthesis and the modification of release of slow-reacting substance of anaphylaxis and histamine. Br. J. Pharmacol.62, 61–66 (1978).Google Scholar
  9. [9]
    P. Pradelles, J. Grassi and J. Maclouf,Enzyme immunoassays of eicosanoids using acetylcholinesterase as label: an alternative to radioimmunoassay. Anal. Chem.57, 1170–1173 (1985).Google Scholar
  10. [10]
    P. Sirois, M. Chagnon, S. Borgeat and P. Vallerand,Role of cyclooxygenase products in the lung action of leukotrienes A 4,B 4,C 4,D 4 and E 4. Pharmacology31, 225–236 (1985).Google Scholar
  11. [11]
    P. J. Piper and M. N. Samhoun,Stimulation of arachidonic acid metabolism and generation of TXA 2 by leukotrienes B 4,C 4 and D 4 in guinea-pig lung in vitro. Br. J. Pharmacol.77, 267–275 (1982).Google Scholar
  12. [12]
    S. Moncada and J. R. Vane,Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A 2,and prostacyclin. Pharmacol. Rev.30, 293–331 (1979).Google Scholar
  13. [13]
    M. Hamberg, J. Svensson and B. Samuelsson,Thromboxanes: A new group of biologically active compounds derived from prostaglandins endoperoxides. Proc. Natl. Acad. Sci. USA72, 2994–2998 (1975).Google Scholar
  14. [14]
    V. Bertelé, A. Flanga, M. Tomasiak, C. Chiabrando, C. Cerletti and G. de Gaetano,Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: Modulatory role of cyclooxygenase products. Blood63, 1460–1466 (1984).Google Scholar
  15. [15]
    V. Bertelé, C. Cerletti, A. Schieppati, G. di Minno and G. de Gaetano,Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet (London)1, 1057–1058 (1981).Google Scholar
  16. [16]
    S. Heptinstal, J. Bevan, S. R. Cockhill, S. P. Hanley and M. J. Parryl,Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb. Res.20, 219–230 (1980).Google Scholar
  17. [17]
    K. Izuka, K. Akahane, D. Momose and M. Nakazawa,Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives. J. Med. Chem.24, 1139–1148 (1981).Google Scholar

Copyright information

© Birkhäuser Verlag 1991

Authors and Affiliations

  • S. Jancar
    • 1
  • C. F. P. Teixeira
    • 2
  • W. Tavares de Lima
    • 1
  • A. Y. Hoshikawa Fujimura
    • 3
  • P. Sirois
    • 4
  1. 1.Departamento de Imunologia, Instituto de Ciências BiomédicasUniversidade de São PauloSão PauloBrasil
  2. 2.Serviço de FarmacologiaInstituto ButantãSão PauloBrasil
  3. 3.Departamento de Análises Clínicas, Faculdade de Ciências FarmaceuticasUSPSão PauloBrasil
  4. 4.Département de Pharmacologie, Faculté de MedicineUniversité de SherbrookeCanada

Personalised recommendations